The VeriStrat® blood-based proteomic test provides predictive and prognostic information for patients diagnosed with advanced non-small cell lung cancer (NSCLC).
- Executive Summary (PDF)
- CPT Descriptor (PDF)
- Peer-Reviewed Publications & Supporting Data
- Discovery (Taguchi et al. 2007)
- Clinical Validation (Carbone et al. 2012, Stinchcombe et al. 2013, Grossi et al. 2016, Buttigliero et al. 2018)
- Prospective Validation (Gregorc et al. 2014)
- Clinical Utility (Akerley et al. 2017)
- Health Economics and Outcomes Research (Page et al. 2017, Page_Argento. 2017)
- List price $4,510
The GeneStrat® blood-based genomic portfolio provides guideline-recommended actionable mutations for patients with NSCLC to expedite time to treatment.
- Executive Summary (PDF)
- CPT Descriptor (PDF)
- Peer-Reviewed Publications & Supporting Data
- Discovery & Validation (Mellert et al. 2017)
- Clinical Utility (Bowling et al., Mattingly et al.)
- Health Economic & Outcomes Research (Magee et al.)
- List price $2,800
The GeneStrat NGS test is a blood-based assay utilizing Next Generation Sequencing (NGS) methodology to assess cell-free nucleic acids from patients with advanced cancer.
- Executive Summary (PDF)
- CPT Descriptor (PDF)
- Peer-Reviewed Publications & Supporting Data
- List price $4,855
.jpg?width=318&name=nodify-cdt-line-540-risk-(R).jpg)
The Nodify CDT® blood-based lung nodule test helps identify patients with a higher risk of malignancy that can be prioritized for diagnostic intervention, potentially avoiding delays in lung cancer diagnoses and find cancer sooner.
- Executive Summary (PDF)
- Peer-Reviewed Publications & Supporting Data
- Discovery (Chapman et afl. 2012)
- Clinical Validation (Boyle et al. 2011, Healey et al. 2017)
- Clinical Utility (Massion et al. 2017, Jett et al. 2017)
- Health Economic & Outcomes Research (Edeslberg et al. 2018, Sutton et al. 2020)
- List price $1,085
The Nodify XL2® blood-based lung nodule test helps identify patients with a lower risk of malignancy that can be safely monitored with follow-up CT scans, potentially alleviating patient anxiety and avoiding unnecessary invasive diagnostic procedures.
- Executive Summary (PDF)
- CPT Descriptor (PDF)
- Peer-Reviewed Publications & Supporting Data
- Discovery (Li et al. 2013, Kearney et al. 2017)
- Clinical Validation (Silvestri et al. 2019 PANOPTIC, Tanner et al. 2018 poster)
- Clinical Utility (ORACLE Study Ongoing)
- List price $4,400